Mutation News and Research

RSS

New targets found for potential intervention in breast cancer

Scientists from the Florida campus of The Scripps Research Institute have found new targets for potential intervention in breast cancer. These new targets could eventually increase effectiveness and reduce the undesirable side effects associated with current treatments.

6 Jun 2014

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen, Inc. and the University of Colorado today announced exclusive license agreements that allow for Ocugen to continue developing two drug candidates for the treatment for ophthalmology indications, and that one of the assets, OCU100, recombinant lens epithelium derived growth factor 1-326 (LEDGF1-326), received orphan-drug status from the U.S. Food and Drug Administration for treatment of retinitis pigmentosa (RP), a rare eye disease.

6 Jun 2014

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics, a privately held company dedicated to bringing new anti-cancer therapies to market, announced today (June 4) that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

5 Jun 2014

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

Research to Prevent Blindness (RPB), the leading eye research foundation, is providing $500,000 to accelerate the development of treatments for Retinitis Pigmentosa (RP) -- a family of retinal diseases that progressively create extreme tunnel vision, loss of night vision and leave affected patients legally blind by the age of 40.

5 Jun 2014

Whole genome sequencing reveals severe intellectual disability in patients

With a new technique, which at once studies the whole genome, a genetic cause can be identified in six out of ten children with severe intellectual disability. This makes the method more successful than all the usual methods together.

5 Jun 2014

Four new genes cause inherited breast cancer risk

Four new genes have been added to the growing list of those known to cause increased breast cancer risk when mutated through the efforts of researchers at Huntsman Cancer Institute (HCI) at the University of Utah, who lead an international consortium working to find more gene mutations that cause inherited breast cancer susceptibilities.

5 Jun 2014

My Cancer Genome unveils second-generation mobile app

My Cancer Genome (MCG), an online precision cancer medicine tool developed by researchers at Vanderbilt-Ingram Cancer Center, has unveiled a free, second-generation mobile app that provides even more information about genetic alterations in various types of cancer and the therapies available to treat those alterations.

5 Jun 2014

New gene involved in Parkinson's disease, find researchers

A team of UCLA researchers has identified a new gene involved in Parkinson's disease, a finding that may one day provide a target for a new drug to prevent and potentially even cure the debilitating neurological disorder.

5 Jun 2014

Son's vulnerability for alcohol use disorders could be shaped by father

Even before conception, a son's vulnerability for alcohol use disorders could be shaped by a father who chronically drinks to excess, according to a new animal study from the University of Pittsburgh School of Medicine.

5 Jun 2014

New process to help select personalized treatment options for patients with lung adenocarcinoma

Moffitt Cancer Center researchers, in collaboration with the Lung Cancer Mutation Consortium, have developed a process to analyze mutated genes in lung adenocarcinoma to help better select personalized treatment options for patients.

4 Jun 2014

Endocrine Society publishes Clinical Practice Guideline for treatment of rare adrenal tumors

The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of two types of rare adrenal tumors - pheochromocytomas and paragangliomas - that can raise the risk of cardiovascular disease and even death if left untreated.

4 Jun 2014

Pathway Genomics introduces BRCA One for One program to detect breast and ovarian cancer

Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it has launched BRCATrueTM, a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer.

3 Jun 2014

Eventual drug resistance prevents long-term cure in most patients with metastatic melanoma

A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.

3 Jun 2014

Breast cancer worry, risk behavior higher among teenage girls

Teenage girls with a familial or genetic risk for breast cancer worry more about getting the disease, even when their mother has no history, compared to girls their age with no known high risks, according to new data presented today by researchers from Penn Medicine's Abramson Cancer Center at the annual meeting of the American Society of Clinical Oncology in Chicago (Abstract #9527).

3 Jun 2014

CHLA researchers develop novel NextGen sequencing approach for retinoblastoma

Researchers at Children's Hospital Los Angeles have developed a unique next-generation sequencing test for the gene linked to retinoblastoma. The new approach is both more comprehensive and can be conducted in less time than existing tests - enabling early detection of the cancer's genetic cause, which is critical for optimal treatment outcomes.

3 Jun 2014

Avastin and cetuximab extend life of patients with KRAS wild-type advanced bowel cancer

CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.

3 Jun 2014

NYU Langone scientists identify promising treatment target for Alzheimer's disease

Scientists at NYU Langone Medical Center have identified a compound, called 2-PMAP, in animal studies that reduced by more than half levels of amyloid proteins in the brain associated with Alzheimer's disease.

3 Jun 2014

Variations in BRCA2 and CHEK2 genes can increase lung cancer risk, study finds

New research confirms a vulnerability to lung cancer can be inherited and implicates the BRCA2 gene as harboring one of the involved genetic mutations.

3 Jun 2014

Oncologists urged to consider financial impact of treatments

The American Society of Clinical Oncology is developing a system to rate drugs for advanced cancer based on their likely benefits and side effects, as well as on their price. Meanwhile, better long-term care is urged for the millions who survive the disease and a report details how drugmakers are tailoring treatments to individuals' genetic makeups even though that may affect only small numbers of people.

3 Jun 2014

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.

2 Jun 2014

Mutation News and Research

New targets found for potential intervention in breast cancer

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

Whole genome sequencing reveals severe intellectual disability in patients

Four new genes cause inherited breast cancer risk

My Cancer Genome unveils second-generation mobile app

New gene involved in Parkinson's disease, find researchers

Son's vulnerability for alcohol use disorders could be shaped by father

New process to help select personalized treatment options for patients with lung adenocarcinoma

Endocrine Society publishes Clinical Practice Guideline for treatment of rare adrenal tumors

Pathway Genomics introduces BRCA One for One program to detect breast and ovarian cancer

Eventual drug resistance prevents long-term cure in most patients with metastatic melanoma

Breast cancer worry, risk behavior higher among teenage girls

CHLA researchers develop novel NextGen sequencing approach for retinoblastoma

Avastin and cetuximab extend life of patients with KRAS wild-type advanced bowel cancer

NYU Langone scientists identify promising treatment target for Alzheimer's disease

Variations in BRCA2 and CHEK2 genes can increase lung cancer risk, study finds

Oncologists urged to consider financial impact of treatments

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

Industry Focus eBook - Cell biology (5th edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News